Asset Details
Do you wish to reserve the book?
Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia
Do you wish to request the book?
Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia
2014
Overview
ETV6/RUNX1
(
E/R
) is the most common fusion gene in childhood acute lymphoblastic leukemia. It is responsible for the initiation of leukemia but also indispensable for disease maintenance and propagation, although its function in these latter processes is less clear. We therefore investigated the effects of the perceived p53 pathway alterations in model cell lines and primary leukemias and, in particular, how E/R upregulates MDM2, the predominant negative regulator of p53. We found that E/R transactivates MDM2 in both p53
+/+
and p53
−/−
HCT116 cells by binding to promoter-inherent RUNX1 motifs, which indicates that this activation occurs in a direct and p53-independent manner. Treatment of
E/R
-positive leukemic cell lines with Nutlin-3, a small molecule that inhibits the MDM2/p53 interaction, arrests their cell cycle and induces apoptosis. These phenomena concur with a p53-induced expression of p21, pro-apoptotic BAX and PUMA, as well as caspase 3 activation and poly ADP-ribose polymerase cleavage. The addition of DNA-damaging and p53-activating chemotherapeutic drugs intensifies apoptosis. Moreover, Nutlin-3 exposure leads to an analogous p53 accumulation and apoptotic surge in
E/R
-positive primary leukemic cells. Our findings clarify the role of p53 signaling in
E/R
-positive leukemias and outline the potential basis for its therapeutic exploitation in this setting.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Child
/ Chromatin Immunoprecipitation
/ Core Binding Factor Alpha 2 Subunit - genetics
/ ETS Translocation Variant 6 Protein
/ Humans
/ Leukemia
/ Medicine
/ Mutation
/ Oncology
/ Original
/ Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics
/ Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism
/ Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology
/ Proteins
/ Proto-Oncogene Proteins c-ets - genetics
/ Proto-Oncogene Proteins c-mdm2 - genetics
/ Real-Time Polymerase Chain Reaction
/ Repressor Proteins - genetics
